1.HCV Infection in Maintenance Hemodialysis Patients:Investigation and Analysis
Guoyou WU ; Aizhou ZHUANG ; Jie ZHU ; Lingjiao WU
Chinese Journal of Nosocomiology 2006;0(12):-
OBJECTIVE To investigate the HCV infection and the distribution condition of HCV subtype in maintenance hemodialysis patients.METHODS A total of 210 cases with maintenance hemodialysis were recruited into this study.Serum samples were tested for anti-HCV antibodies using ELISA and HCV RNA by RT-PCR.At the same time,samples with anti-HCV IgM positive were identified for their subtype.RESULTS In all cases,91 cases(43.3%) were anti-HCV IgM positive,87 cases(41.4%) were anti-HCV IgG positive,and 105 cases(50.0%) were HCV-RNA positive.Eighty one cases(38.6%) were positive for all HCV infection markers,and 117 cases(55.7%) were positive for at least one marker.Compared that of cases with negative all HCV infection markers,the levels of ALT,AST,LDH and ?-GT in maintenance hemodialysis patients whose at least one marker was positive were significantly higher.Of 91 cases with positive anti-HCV IgM,55 cases(64.4%) were with type 1,9 cases(9.8%) with type 2,13 cases(14.2%) with type 3,and 7 cases(7.6%) with type 6.In addition,3 cases(3.2%) with types 1+6,and 4 cases(4.3%) were with types 1+3.CONCLUSIONS The infectious ratio of HCV in maintenance hemodialysis patients is high,particularly that of type 1 HCV is the highest.
2.The role of nuclear factor-kappaB in the induction of nitric oxide and tumor necrosis factor-alpha by Astragalus mongholicus polysaccharides in macrophages
Jie ZHU ; Zhen XIAO ; Yueshuang SHEN ; Guoyou WU
Chinese Journal of Microbiology and Immunology 2010;30(6):511-515
Objective To explore the molecular and cell signal transduction mechanism of Astragalus mongholicus polysaccharides (ASP) on macrophage. Methods After stimulating RAW264.7, the change in value of NF-κB was determined by Western blot. The induction of NO and secretion of TNF-α by ASP in macrophage was observed with or without inhibitor of NF-κB using Griess method. Moreover, protein levels of TNF-α secreted by macrophage were investigated with ELISA in respond to ASP. Results 4 h after stimulation by 100 μg/ml ASP, the concentration of NF-κB in nucleus increased significantly, peaked at 6 h. 16 h after stimulation by 100 μg/ml ASP, the activity of iNOS[(23.54±2.41) U/mg protein; P<0.01], producton of NO [(18.9±1.5)μmol/L, P<0.01] and level of TNF-α[(81.2±16.7)pg/ml, P<0.0l] in macrophage were improved markedly. Blocking NF-κB with inhibitor results in decreased levels of NO and TNF-α. Conclusion The results suggest that NF-κB play an important role in induction of NO and TNF-α by ASP in macrophage.
3.Meta-analysis of Effectiveness and Safety of Butylphthalide Capsules Combined with Xueshuantong Injec-tion in the Treatment of Acute Cerebral Infarction
Fengbo WU ; Guoyou DAI ; Xiaorong FENG ; Ting XU ; Jian LI
China Pharmacist 2017;20(2):314-317
Objective:To evaluate the effectiveness and safety of butyl phthalide capsules combined with Xueshuantong injection in the treatment of acute cerebral infarction (ACI). Methods: Cochrane Library, Medline, Embase, SCI, CBM, CNKI, VIP and Wanfang databases were searched from the building time to May 2016. The enrolled randomized controlled trails were studied by using Cochrane system evaluation methods to perform methodological quality assessment, and RevMan 5. 2 software was used to carry out Me-ta-analysis. Results:A total of 7 randomized controlled trails including 640 patients were enrolled. The results of Meta-analysis dem-onstrated that the effective rate of butylphthalide capsules combined with Xueshuantong injection was superior to that of Xueshuantong injection (RR=1. 33, 95%CI:1. 16-1. 52, P<0. 0001), butylphthalide (RR=1. 45, 95%CI:1. 15-1. 83, P=0. 002) and blank control (RR=1. 31, 95%CI:1. 08-1. 57, P=0. 005). NHISS of butylphthalide capsules combined with Xueshuantong injection was higher than that of Xueshuantong injection (MD=4. 63, 95%CI:3. 38-5. 87, P<0. 00001) and blank control (MD=6. 85, 95%CI:4. 90-8. 80, P<0. 00001). There was no significant difference in adverse drug reactions. Conclusion: Butylphthalide capsules combined with Xueshuantong injection is effective for the therapy of ACI. However, due to the limited quantity and quality of the in-cluded studies, larger scale trials are needed.
4.Effect of Astragalus injection on the expression of p53 mRNA in human nasopharyngeal carcinoma cell line CNE2 xenograft in nude mice
Shixiu WEI ; Chengjun LIU ; Guoyou SANG ; Muyan LI ; Hua WU
Chinese Pharmacological Bulletin 2003;0(07):-
Aim To study the effect of Astragalus injection on tumor growth inhibition of human nasopharyngeal carcinoma cell strain CNE2 xenograft in BALB/c nude mice,and explore the possible mechanisms.Methods CNE2 cells were injected subcutaneously into nude mice to establish model of transplanted tumor.Twenty one model nude mice were divided randomly into three groups treated with intraperitoneal injection,viz the model group given normal saline 10 ?l?(g?d)~-1,the positive control group given Cisplatin 30 mg?m~-2 every fourteen days and given normal saline sodium 10 ?l?(g?d)~-1 in other days,and the treatment group given Astragalus injection 10.40 mg?(g?d)~-1.The above administrations for groups lasted 4 weeks.The inhibitory effect of Astragalus injection on the growth of tumors in nude mice was observed,and the inhibitory rate and the relative tumor proliferation rate were calculated.The expression levels of p53 mRNA in tumor tissues were determined by FQ-PCR.Results After four weeks′treatment,the volumes of tumors in nude mice from the model group,the Cisplatin group,the Astragalus injection group were(1.51?0.25)cm~3,(0.91?0.35)cm~3 and(1.04?0.51)cm~3 respectively.Compared with the model group,the tumor volumes in the Cisplatin group and in the Astragalus injection group were smaller(P0.05).Conclusions The results suggest that Astragalus injection shows inhibitory effect on the growth of human nasopharyngeal carcinoma cell strain CNE2 xenograft in BALB/c nude mice,while it can not be claimed that Astragalus injection may affect the expression level of p53 mRNA in transplanted tumor tissue.
5.Platelet-rich plasma versus corticoid in the treatment of chronic lateral elbow epicondylitis
Guoyou ZOU ; Weitao JIA ; Minqian ZHENG ; Ruli ZHU ; Hongbing LIU ; Wensheng ZHANG ; Ya WU
Chinese Journal of General Practitioners 2013;12(11):916-918
A total of 52 patients with chronic lateral epicondylitis were randomly assigned into platelet-rich plasma (PRP) (n =28) or corticosteroid (n =24) group.The visual analog pain scale (VAS) and Mayo elbow score had no significant difference between two groups within 1 week post-treatment.However,VAS and Mayo elbow score improved more significantly in PRP group versus corticosteroid group at Month 1 and 6 post-treatment (P < 0.05).The PRP trigger point injection treatment of elbow lateral epicondylitis achieved clinical outcomes and it was superior to glucocorticoid treatment.
6.Platelet-rich plasma trigger point injection treatment for chronic achilles insertion tendonitis
Guoyou ZOU ; Weitao JIA ; Minqian ZHENG ; Xiaozu XU ; Zhengchun CAO ; Jun YIN ; Ya WU
Chinese Journal of General Practitioners 2013;12(8):657-659
Retrospective analysis was performed for the clinical data of 15 chronic insertion achilles tendinitis patients undergoing platelet-rich plasma (PRP) trigger point injection.The scores of Validated Victorian Institute of Sports Assessment-Achilles (VAS-A) and foot function index (FFI) improved greatly versus pre-treatment (all P < 0.05).Tendon insertion structure inflammation decreased significantly on magnetic resonance imaging.At the last follow-up,all patients recovered normal gait and daily activity.The trigger point injection of PRP is efficacious for chronic insertion achilles tendinopathy.
7.Short term therapeutic effect on treatment of postoperational large intestine carcinoma by Fupiyiwei decoction combined with chemotherapy and it's effect on immune function.
Guolin WU ; Guoyou YU ; Jianping LI ; Fulin XIONG
China Journal of Chinese Materia Medica 2010;35(6):782-785
OBJECTIVETo investigate short term clinical therapeutic effect of fupiyiwei decoction (FPYWD) combined with chemotherapy in treating postoperational large intestine carcinoma and the effect on immune function.
METHODThe 58 cases of postoperational large intestine carcinoma were randomly divided into the traditional Chinese medicine (TCM) group (33 cases) and the control group (25 cases). The toxic and adverse reaction, Karnofsky score and clinical therapeutic effect during chemotherapy were observed, and the level of subgroup of T cells CD3, CD4, CD8 and NK cells were detected. Before and after treatment 28 healthy adult were regarded as normal group.
RESULTThere was no significant difference in clinic therapeutic effect between the TCM group and the control group after 12 chemotherapy treatment courses. But the quality of life the TCM group remarkably better than in the control group (P < 0.05), while the incidence rate of toxic and adverse reaction of chemotherapy in the former group was lower than in the latter (P < 0.05). The level of CD3+, CD4+ T cell and the viability of NK cells in all patients decreased during the chemotherapy treatment course while the level of CD8+ T cell increased, the level of CD3+ T cell and NK cells in peripheral blood in patients increased after treatment, but was lower than in normal group. The level of CD8+ T cell was decreased and was lower than in normal group. There was no significant difference (P < 0.05). The level of CD4 T cell after TCM group, there was significant different in CD4+ T cell between TCM group and control group, normal group (P < 0.05). The viability of NK cell increased but there was no significant difference between the two group.
CONCLUSIONFupiyiwei decoction (FPYWD) is effective in prevention and treatment of the toxic and adverse effects of chemotherapy of postoperational large intestine carcinoma, and can improve quality of life and immune function of patients. increase the effective of chemotherapy.
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Colorectal Neoplasms ; drug therapy ; Combined Modality Therapy ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Killer Cells, Natural ; Male ; Medicine, Chinese Traditional ; methods ; Middle Aged ; Neoplasm Staging ; Phytotherapy ; T-Lymphocyte Subsets ; immunology ; T-Lymphocytes ; immunology
8.A novel inhibitor of N 6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities.
Guoyou XIE ; Xu-Nian WU ; Yuyi LING ; Yalan RUI ; Deyan WU ; Jiawang ZHOU ; Jiexin LI ; Shuibin LIN ; Qin PENG ; Zigang LI ; Hongsheng WANG ; Hai-Bin LUO
Acta Pharmaceutica Sinica B 2022;12(2):853-866
N 6-methyladenosine (m6A) modification is critical for mRNA splicing, nuclear export, stability and translation. Fat mass and obesity-associated protein (FTO), the first identified m6A demethylase, is critical for cancer progression. Herein, we developed small-molecule inhibitors of FTO by virtual screening, structural optimization, and bioassay. As a result, two FTO inhibitors namely 18077 and 18097 were identified, which can selectively inhibit demethylase activity of FTO. Specifically, 18097 bound to the active site of FTO and then inhibited cell cycle process and migration of cancer cells. In addition, 18097 reprogrammed the epi-transcriptome of breast cancer cells, particularly for genes related to P53 pathway. 18097 increased the abundance of m6A modification of suppressor of cytokine signaling 1 (SOCS1) mRNA, which recruited IGF2BP1 to increase mRNA stability of SOCS1 and subsequently activated the P53 signaling pathway. Further, 18097 suppressed cellular lipogenesis via downregulation of peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer-binding protein alpha (C/EBPα), and C/EBPβ. Animal studies confirmed that 18097 can significantly suppress in vivo growth and lung colonization of breast cancer cells. Collectively, we identified that FTO can work as a potential drug target and the small-molecule inhibitor 18097 can serve as a potential agent against breast cancer.